CVE:DMT Small Pharma (DMT) Stock Price, News & Analysis C$0.15 -0.01 (-6.25%) As of 10/20/2023 Add Compare Share Share Stock Analysis Stock Analysis About Small Pharma Stock (CVE:DMT) Get Small Pharma alerts:Sign Up Key Stats Today's RangeC$0.15▼C$0.1650-Day RangeC$0.15▼C$0.1552-Week RangeC$0.06▼C$0.22Volume1.89 million shsAverage Volume296,159 shsMarket CapitalizationC$50.37 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage. Its preclinical stage programs include SPL029, an oral formulation of a tryptamine to treat depressive disorder. The company is headquartered in London, the United Kingdom. As of October 23, 2023, Small Pharma Inc. operates as a subsidiary of Cybin Inc. Read More Receive DMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Small Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DMT Stock News HeadlinesColorado shop offers DMT microdosing sessions for healingApril 10, 2026 | yahoo.comShort-acting psychedelic DMT shows promise as a rapid treatment for major depressive disorderMarch 31, 2026 | msn.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 14 at 1:00 AM | Awesomely (Ad)Ayahuasca-derived DMT study shows positive effects on depression therapy in trialsMarch 30, 2026 | yahoo.comSingle DMT dose eased depression-like symptoms in mice, study findsMarch 11, 2026 | msn.comAyahuasca psychedelic DMT shows promise as depression therapyFebruary 25, 2026 | theguardian.comSingle dose of potent psychedelic slashes depression in clinical trialFebruary 22, 2026 | msn.comSingle DMT dose delivers long-lasting relief from depressionFebruary 18, 2026 | msn.comSee More Headlines DMT Stock Analysis - Frequently Asked Questions How have DMT shares performed this year? Small Pharma's stock was trading at C$0.15 at the beginning of the year. Since then, DMT stock has increased by 0.0% and is now trading at C$0.15. Industry, Sector and Symbol Stock ExchangeCVE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolCVE:DMT CIKN/A Webwww.smallpharma.co.uk Phone44 78 1212 1944FaxN/AEmployees13Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$19.31 million Net MarginsN/A Pretax MarginN/A Return on Equity-116.90% Return on Assets-66.00% Debt Debt-to-Equity Ratio5.95 Current Ratio2.63 Quick Ratio6.28 Sales & Book Value Annual Sales-C$1.16 thousand Price / Sales-43,343.80 Cash FlowC$0.13 per share Price / Cash Flow1.13 Book ValueC$0.03 per share Price / Book5.00Miscellaneous Outstanding Shares335,770,000Free FloatN/AMarket CapC$50.37 million OptionableNot Optionable Beta0.86 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (CVE:DMT) was last updated on 10/20/2023 by MarketBeat.com Staff. From Our PartnersWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on p...Weiss Ratings | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Small Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Small Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
